Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Total Inventories : ¥57.48 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Total Inventories?

Chongqing Genrix Biopharmaceutical Co's total inventories for the quarter that ended in Sep. 2024 was ¥57.48 Mil. Chongqing Genrix Biopharmaceutical Co's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was ¥58.60 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Chongqing Genrix Biopharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was ¥4.56.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Sep. 2024 was 2,214.11.

Inventory Turnover measures how fast the company turns over its inventory within a year. Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.04.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 4.70.

Chongqing Genrix Biopharmaceutical Co Total Inventories Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Total Inventories Chart

Chongqing Genrix Biopharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

11.19

15.85

33.66

56.33

55.45

Chongqing Genrix Biopharmaceutical Co Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Inventories	Get a 7-Day Free Trial										61.09	55.45	59.89	59.72	57.48

Chongqing Genrix Biopharmaceutical Co Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Chongqing Genrix Biopharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

	Net-Net Working Capital Per Share (Q: Sep. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2560.514	+	0.75 * 13.816	+	0.5 * 57.479	-	927.17
-	0	-	0)	/	366.680
=	4.56

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	58.598	/	2.415	*	365 / 4
	=	2,214.11

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	2.415	/	58.598
	=	0.04

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chongqing Genrix Biopharmaceutical Co's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	58.598	/	12.475
	=	4.70

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Chongqing Genrix Biopharmaceutical Co Total Inventories Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Chongqing Genrix Biopharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338

Website

http://www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Executives

Jiang Ren Sheng

Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines